Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALXN 2220

Next Previous
Search
Drug Profile

ALXN 2220

Alternative Names: ALXN-2220; NI-006

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Alexion AstraZeneca Rare Disease; Neurimmune Therapeutics
  • Class Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cardiomyopathies
  • Preclinical Familial amyloid neuropathy

Most Recent Events

  • 14 Oct 2024 ALXN 2220 receives Fast Track designation for Cardiomyopathies [IV,Infusion] in USA
  • 30 Aug 2024 Efficacy and adverse event data from a phase-I trial in Cardiomyopathies presented at the Annual Congress of the European Society of Cardiology 2024 (ESC-Card-2024)
  • 29 May 2024 Adverse events data from the Phase-I trial in Cardiomyopathies released by AstraZeneca

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top